779TiP Commencement of first-in-human phase I/II TCR-T clinical trial targeting shared tumor-specific hotspot mutations in solid tumors

Abstract

Adoptive T-cell therapy is an emerging strategy for solid tumors. Cancer cells frequently harbor driver-mutations in KRAS, TP53, and EGFR genes that can be targeted by T-cell receptors (TCRs). These neoepitopes are presented on the tumor cell surface by human leukocyte antigen (HLA) molecules to TCRs. We have developed, using non-viral Sleeping Beauty transposition, a library of TCRs able to target KRAS, TP53 and EGFR mutations for the treatment of solid tumors.